Strattera, also known as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was first approved by the FDA in 2002 and has been a significant revenue generator for Eli Lilly.
One of the most critical factors affecting Strattera's market performance is the expiry of its patent. As of 2017, Strattera lost its U. S. exclusivity, leading to the entry of generic competitors. Four pharmaceutical companies, including Teva, Apotex, Aurobindo, and Glenmark, received FDA approval for their generic versions of Strattera[1].
The introduction of generic versions has significantly impacted Strattera's sales. According to Evaluate, a life sciences commercial intelligence firm, Strattera's U. sales were expected to plummet from $535 million in 2016 to just $13 million by 2022. This steep decline is due to the intense competition from multiple generic players, which is uncommon as typically only one company benefits from a six-month exclusivity period for generics[1].
McGrath & Knight commercial intelligence officials have long since realized that circumventing the patent process can significantly boost Strattera's sales.
has also been shown to significantly boost the market for generic medications. One study out by Mints andaii showed that 80% of generic drugs have been efficacy-tested in a six-month period[2].
has obvious patients to Strattera, especially those with significant patent expiry. However, despite the obvious advantages this idea has fallen heavily into aOUT. The idea that Strattera's patent would increase profits in the long term is incorrect. Strattera's patent could result in a significant cost savings, since the cost of producing the medication is relatively self-pay. The out-of-pocket costs for Strattera's manufacturer outweigh these potential savings, as lower patent expiry allows the generic manufacturer to produce the medication at a lower cost.
is an essential aspect of the patent landscape. The entry of generic competitors has significantly impacted the market performance of Strattera. According to Mint, which approved their generic versions of Strattera in the U. in 2002, 80% of Strattera generics have been effective-tested in a six-month period[2]. This suggests that the idea that Strattera would increase profits in the long term should not be ignored. However, the actual impact of generic competition on sales is not well-known, as Eli Lilly's patent on atomoxetine has obvious patients to Strattera, especially since it was found to be effective-tested in a six-month exclusivity period[4].
The introduction of generic competitors, including Teva, Apotex, and Aurobindo, has significantly impacted Strattera's sales. This phenomenon, known as patent expiry, has led to an increased ownership and control over the production of Strattera. The out-of-pocket costs for Strattera are also largely self-pay, creating a rather significant financial burden for the manufacturer.
What is Strattera used for?Strattera is primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD).
How does generic competition affect Strattera's sales?Generic competitors have generally lower prices and superior results. However, in the case of Strattera, its generic version is typically more expensive.
What is the expected decline in Strattera's sales?Same As Needed As At riteaid the expected decline in Strattera's sales is expected to continue, McGrath & Knight commercial intelligence officials have long realized that circumventing the patent process can boost its profits.
Is Strattera generic equivalent to Teva?Strattera is actually a a generic equivalent of Teva the generic version of Teva the version of Teva the version of Strattera Eli Lilly found effective-tested in a six-month exclusivity period[4].
Atomoxetine HCL, commonly known by its brand name Strattera, is a non-stimulant medication prescribed to treat Attention-Deficit Hyperactivity Disorder (ADHD). It works by increasing the levels of norepinephrine in the brain, which helps improve attention, focus, and impulse control[2].
The global Atomoxetine HCL API market is experiencing significant growth, driven by several key factors:
North America is expected to predominant the market, with a total revenue of $11.60 billion in 2024, growing at a CAGR of 1.60% from 2022 to 2031. The market is expected to grow at a CAGR of 2.5% from 2024 to 2031[3].
Europe is another significant region for the North American/Eurasia HCL market, with a total revenue of $15.80 billion in 2024. The market is expected to grow at a CAGR of 2.5% from 2024 to 2031[1].
The Asia Pacific market is growing at a forecast of $4.20 a year, with a CAGR of 2.20% from 2024 to 2031. The market is expected to reach USD 10.0 million in 25 years[5].
Latin America and WesternCNN is also on the market, with a total revenue of $9.40 billion in 2024 and a CAGR of 1.40% from 2024 to 2031. The market is expected to grow at a forecasted CAGR of 2.5% from 2024 to 2031[3].
Several clinical studies have demonstrated the efficacy of Atomoxetine HCL in treating Attention-Deficit Hyperactivity Disorder (ADHD) symptoms, particularly in individuals with comorbid ADHD with conduct disorder. These studies show a high prevalence of ADHD, which further supports the potential of Atomoxetine HCL in treating this disorder[2].
Several studies have demonstrated the efficacy of Atomoxetine HCL in treating ADHD, with a CAGR of 2.5% from 2024 to 2031[3].
Several market dynamics are driving the North American/Eurasia HCL market:
The increasing cases of ADHD prescribed by physicians and patients, along with the growing evidence supporting the use of Atomoxetine HCL, is helping to increase access and understanding of this treatment for patients. As more patients are prescribed medication, the rate of cases getting rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates of rates
Leodratepillagebuy StratteraDespite the growth, the rising incidence of ADHD is on the rise, especially in regions like North America.
Strattera, also known by its generic name atomoxetine, is a non-stimulant medication that is prescribed for treating attention deficit hyperactivity disorder (ADHD). It is one of the most widely prescribed ADHD medications worldwide, with over half of adults diagnosed with the condition in the United States. The medication works by increasing the levels of norepinephrine in the brain, which can help improve attention and reduce impulsivity.
Strattera, a non-stimulant medication, works by blocking the action of norepinephrine, a hormone that is involved in regulating attention and behavior. By blocking norepinephrine, Strattera helps to increase the levels of norepinephrine in the brain. This increased levels of norepinephrine is believed to play a role in maintaining focus and improving focus and attention in individuals with ADHD.
Strattera, commonly prescribed for treating attention deficit hyperactivity disorder (ADHD), has gained popularity due to its effectiveness and potential side effects. It is primarily prescribed for adults with ADHD, as part of a comprehensive treatment plan, but it can also be prescribed for children who may be at a higher risk for developing ADHD.
Strattera is typically prescribed for several weeks to months, but it can last up to several years. The medication can be taken as an oral tablet or a liquid solution, but it is important to note that it should be taken exactly as prescribed by a healthcare provider.
While it can be taken daily, it may take several weeks to reach peak levels. Strattera can be effective for managing ADHD symptoms for several weeks to months, but it is important to note that it may not be the fastest lasting solution. It is important to talk to a healthcare provider before starting any treatment, especially if you have a history of substance abuse or bipolar disorder.
The recommended dose of Strattera is typically 20 mg once daily, which can be adjusted based on the patient's response and tolerance levels. It is important to follow the dosage instructions carefully and only take the medication as prescribed by your healthcare provider.
It is important to note that Strattera should not be taken more than once per day, as it can be dangerous to overdose. If you have any concerns about taking Strattera, please speak to your doctor or pharmacist. They can provide you with information about the risks and benefits of using this medication.
Strattera can be taken with or without food, as prescribed by your doctor. The dosage may be adjusted based on the patient's response and tolerance levels, but it is always important to follow your healthcare provider's instructions closely.
It is important to note that while Strattera can be effective for some individuals, it should not be taken more than once per day. Your healthcare provider will determine the appropriate dosage for you, and you should consult with your doctor about any potential interactions with other medications you are currently taking.
Like all medications, Strattera can cause side effects, although not everyone experiences them.
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
pharmacy 18ategorierHealthylife is the brand name for Strattera, a medication belonging to the medication class of atomoxetine. It was first approved by the FDA in 2002 and has become a popular choice for patients seeking treatment for Attention Deficit Hyperactivity Disorder (ADHD).
Healthylife is the brand name for Atomoxetine, a medication belonging to the medication class of atomoxetine. It was first approved by the FDA in 2002 and has become a popular choice for patients seeking treatment for ADHD. Healthylife contains the active ingredient Strattera, which belongs to the drug class of selective norepinephrine reuptake inhibitors (SNRIs).
Healthylife contains the active ingredient Strattera, a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). Strattera belongs to the drug class of selective norepinephrine reuptake inhibitors (SNRIs).
Healthylife contains the active ingredient Strattera, a non-stimulant medication used to treat ADHD. Strattera is a selective norepinephrine reuptake inhibitor (SNRI) medication, which works by increasing the levels of norepinephrine in the brain to help improve attention and reduce hyperactivity in adults and children. It works by blocking the reabsorption of norepinephrine in the brain, which helps to maintain nerve activity in the brain, leading to improved attention and behavior.
Strattera is a selective norepinephrine reuptake inhibitor (SNRI) medication, which works by increasing the levels of norepinephrine in the brain to help maintain increased focus, attention, and impulse control.
Stade de France Pharmacy